Human variability and noncancer risk assessment - An analysis of the default uncertainty factor

被引:189
作者
Renwick, AG
Lazarus, NR
机构
[1] Univ Southampton, Clin Pharmacol Grp, Southampton SO16 7PX, Hants, England
[2] Open Univ, SE Reg, E Grinstead AH19 1ES, W Sussex, England
关键词
uncertainty factor; human variability; toxicokinetics; toxicodynamics; interindividual differences;
D O I
10.1006/rtph.1997.1195
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A 10-fold uncertainty factor is used for noncancer risk assessments to allow for possible interindividual differences between humans in the fate of the chemical in the body (kinetics) and target organ sensitivity (dynamics). Analysis of a database on the variability in each of these aspects is consistent with an even subdivision of the 10-fold factor into 10(0.5) (3.16) for kinetics and 10(0.5) (3.16) for dynamics. Analysis of the number of subjects in a normally and log-normally distributed population which would not be covered by factors of 3.16 supports this subdivision and also the use of a 10-fold factor to allow for both aspects. Analysis of kinetic data for subgroups of the population indicates that the standard default value of 3.16 for kinetics will not be adequate for all routes of elimination and all groups of the population. A scheme is proposed which would allow the selection of appropriate default uncertainty factors based on knowledge of the biological fate and effects of the chemical under review. (C) 1998 Academic Press.
引用
收藏
页码:3 / 20
页数:18
相关论文
共 142 条
[81]  
Kinirons MT, 1996, BRIT J CLIN PHARMACO, V41, P69
[82]   PHARMACODYNAMIC ACTION AND PHARMACOKINETICS OF MOXONIDINE AFTER SINGLE ORAL-ADMINISTRATION IN HYPERTENSIVE PATIENTS [J].
KIRCH, W ;
HUTT, HJ ;
PLANITZ, V .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (12) :1088-1095
[83]   CLINICAL PHARMACOKINETICS OF NEWER CEPHALOSPORINS [J].
KLEPSER, ME ;
MARANGOS, MN ;
PATEL, KB ;
NICOLAU, DP ;
QUINTILIANI, R ;
NIGHTINGALE, CH .
CLINICAL PHARMACOKINETICS, 1995, 28 (05) :361-384
[84]   PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF MIDAZOLAM EFFECTS ON THE HUMAN CENTRAL NERVOUS-SYSTEM [J].
KOOPMANS, R ;
DINGEMANSE, J ;
DANHOF, M ;
HORSTEN, GPM ;
VANBOXTEL, CJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) :14-22
[85]   WORKSHOP ON THE SCIENTIFIC EVALUATION OF THE SAFETY FACTOR FOR THE ACCEPTABLE DAILY INTAKE (ADI) - EDITORIAL SUMMARY [J].
KROES, R ;
MUNRO, I ;
POULSEN, E .
FOOD ADDITIVES AND CONTAMINANTS, 1993, 10 (03) :269-273
[86]  
LECOZ F, 1995, CLIN PHARMACOL THER, V57, P533
[87]   PHARMACOKINETIC-PHARMACODYNAMIC MODELING IN DRUG DEVELOPMENT - APPLICATION TO THE INVESTIGATIONAL OPIOID TREFENTANIL [J].
LEMMENS, HJM ;
DYCK, JB ;
SHAFER, SL ;
STANSKI, DR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :261-271
[88]   PHARMACODYNAMICS OF ALFENTANIL - THE ROLE OF PLASMA-PROTEIN BINDING [J].
LEMMENS, HJM ;
BURM, AGL ;
BOVILL, JG ;
HENNIS, PJ ;
GLADINES, MPRR .
ANESTHESIOLOGY, 1992, 76 (01) :65-70
[89]   A NEW APPROACH TO DERIVING COMMUNITY EXPOSURE GUIDELINES FROM NO-OBSERVED-ADVERSE-EFFECT LEVELS [J].
LEWIS, SC ;
LYNCH, JR ;
NIKIFOROV, AI .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1990, 11 (03) :314-330
[90]   Jejunal permeability and hepatic extraction of fluvastatin in humans [J].
Lindahl, A ;
Sandstrom, R ;
Ungell, AL ;
Abrahamsson, B ;
Knutson, TW ;
Knutson, L ;
Lennernas, H .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) :493-503